Is optic disc drusen a risk factor in young patients with anterior ischaemic optic neuropathy?

This retrospective cross-section multicentre study reviewed 65 patients all younger than 50-years-old with non-arteritic anterior optic neuropathy (NA-AION) between April 2017 and March 2019. The purpose of this study was to investigate if there was a link between Optic Disc...

OCT angiography sign after whiplash

Berlin’s oedema is a rare condition following blunt ocular injury and a rare finding after whiplash injury. This case describes a 48-year-old male who suffered a seventh vertebrae fracture from a traffic accident. Two days later, decreased left eye visual...

Clinical features of ocular syphilis

The study looked at 24 patients (20 males, four females) with serological evidence of syphilitic infection who presented to a tertiary ophthalmic centre. Ocular involvement was the first manifestation of syphilitic disease in 96% and Human Immunodeficiency Virus (HIV) seropositivity...

Intravitreal Ziv-Aflibercept: safety analysis

Ziv-Aflibercept (Zaltrap; Sanofi-Aventis U.S LLS, Bridgewater, NJ) was originally introduced as an intravenous formulation for metastatic colorectal cancer. The adoption of Ziv-Aflibercept in ophthalmic practice was similar to bevacizumab, and reports have previously examined one to two year visual outcomes...

Visual acuity outcomes in Coat’s disease by classification stage

This is a retrospective study of 160 consecutive patients with Coat’s disease under the Shields classification, with Snellen visual acuity (VA) pre and post treatment. Affected eyes were categorised based on the Shields classification: Stage 1: retinal telangiectasia onlyStage 2a:...

Treat-and-extend regimen in treatment of patients with type 3 neovascularisation

Type 3 neovascularisation, also known as retinal angiomatous proliferation is a distinct subtype of neovascular AMD characterised by intraretinal neovascularisation. This retrospective study included 17 eyes diagnosed with type 3 neovascularisation who were changed from pro-re-nata (PRN) based treatment regime...

How accurate is the supplement content in both generic and branded ophthalmology supplements?

This prospective cross-section study compared the concentrations of Vitamin C, Vitamin E, Zinc, and Copper in five dietary supplements including both national and regional brands used for macular degeneration in the United States. They performed a comparative analysis using gas...

VIBIM Study: One-year results of treatment of DME with aflibercept using TnE

The VIBIM study (the treat-and-extend regimen (TER) using intravitreal aflibercept in diabetic macular edema (DME) study) was designed to evaluate the efficacy of the TER using aflibercept in the management of DME for a period of two years. The authors...

Conservative surgical management of optic disc pit maculopathy

Four cases are presented in this case report that illustrates the option of conservative surgical management for optic disc pit complicated by maculopathy (ODP-M). Four men aged 24-67-years-old with no spontaneous resolution of ODP-M for a minimum of three months,...

Ozurdex in epiretinal membrane surgery

This was a prospective multicentre pilot study, looking at the effect of Ozurdex on visual acuity (VA) and central retinal thickness (CRT) in patients undergoing surgery for epiretinal membrane (ERM). Twelve eyes of 12 patients were included in the study....

Silicone oil in rhegmatogenous retinal detachment

Silicone oil (SO), used in complicated retinal detachments, is associated with complications such as cataract, increased intraocular pressure (IOP), keratopathy, cystoid macular oedema (CMO), epiretinal membrane (ERM) and loss of vision. Emulsification of oil can also lead to migration of...

Anatomical and functional outcomes following switching from aflibercept to ranibizumab in NARMD

This is a six-month, prospective, single-arm study in the UK and Germany. A total of 100 patients were enrolled (one in the primary failure group, 99 in the suboptimal treatment response group), treated three-monthly intravitreal ranibizumab injections (0.5mg), and then...